S&P Futures
5,882.75 -13.50 (-0.23%) Dow Futures
43,093.00 -84.00 (-0.19%) Nasdaq Futures
20,453.00 -66.50 (-0.32%) Russell 2000 Futures
2,246.80 -8.70 (-0.39%) Crude Oil
70.35 -0.21 (-0.30%) Gold
2,748.80 +9.90 (+0.36%)
Artelo Biosciences, Inc. (ARTL)
After hours:
| Previous Close | 1.1800 |
| Open | 1.2000 |
| Bid | 0.0000 x 0 |
| Ask | 0.0000 x 0 |
| Day's Range | 1.1982 - 1.2400 |
| 52 Week Range | 1.0000 - 1.7500 |
| Volume | |
| Avg. Volume | 9,575 |
| Market Cap | 4.002M |
| Beta (5Y Monthly) | 1.36 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -3.3500 |
| Earnings Date | Nov 11, 2024 - Nov 15, 2024 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 14.00 |
GlobeNewswireArtelo Biosciences CEO to Participate in Fireside Chat at the Maxim Group Virtual Healthcare Summit on October 16th
SOLANA BEACH, Calif., Oct. 09, 2024 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people living with cancer, pain, dermatologic and neurological conditions today announced that it will be participating in the Maxim Group 2024 Virtual Healthcare Summit being held October 15-17, 2024. Gregory D. Gorgas, CEO of Artelo Biosciences, will be joining Jason McCarthy, Maxim’s Se
- GlobeNewswire
Artelo Biosciences to Present at the H.C. Wainwright 26th Annual Global Investment Conference
SOLANA BEACH, Calif., Sept. 04, 2024 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people living with cancer, pain, dermatologic and neurological conditions today announced that Gregory D. Gorgas, CEO of Artelo Biosciences, will be participating in the H.C. Wainwright 26th Annual Global Investment Conference being held September 9-11, 2024 at the Lotte New York Palace H
